NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Eisai Inc.
Merck Sharp & Dohme LLC
Pfizer
Bristol-Myers Squibb
Bristol-Myers Squibb
National Cancer Institute (NCI)
Pfizer